Ignite Creation Date:
2025-12-25 @ 12:32 AM
Ignite Modification Date:
2026-01-04 @ 12:50 AM
Study NCT ID:
NCT07166367
Status:
TERMINATED
Last Update Posted:
2025-09-10
First Post:
2025-09-03
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for HER2+ Breast Cancer
Sponsor:
National Cancer Centre, Singapore
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | HER2-positive Breast Cancer | View |
Keywords: